Last reviewed · How we verify

Isturisa — Competitive Intelligence Brief

Isturisa (OSILODROSTAT) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cortisol Synthesis Inhibitor. Area: Respiratory.

marketed Cortisol Synthesis Inhibitor Cytochrome P450 11B2, mitochondrial Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Isturisa (OSILODROSTAT) — Recordati. Isturisa blocks the production of cortisol in the adrenal glands by inhibiting the cytochrome P450 11B2 enzyme.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Isturisa TARGET OSILODROSTAT Recordati marketed Cortisol Synthesis Inhibitor Cytochrome P450 11B2, mitochondrial 2020-01-01
Amidate ETOMIDATE Pfizer marketed General Anesthetic [EPC] Cytochrome P450 11B2, mitochondrial 1982-01-01
Zytiga Zytiga Bukwang Pharmaceutical marketed Cytochrome P450 11B2, mitochondrial, Androgen receptor, Cytochrome P450 11B1, mitochondrial
Recorlev LEVOKETOCONAZOLE Strongbridge marketed Cortisol Synthesis Inhibitor [EPC] 2021-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cortisol Synthesis Inhibitor class)

  1. Recordati · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Isturisa — Competitive Intelligence Brief. https://druglandscape.com/ci/osilodrostat. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: